ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΠΉ ΡΠ°ΠΊ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ: ΠΎΡΠΈΠ±ΠΊΠΈ ΡΡΠ°Π΄ΠΈΡΠΎΠ²Π°Π½ΠΈΡ, ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ Π»Π΅ΡΠ΅Π½ΠΈΡ, ΡΠ°ΠΊΡΠΎΡΡ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π°
ΠΠ΅ΡΠΌΠΎΡΡΡ Π½Π° ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠ°ΠΌΡΡ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΡ ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊ, ΡΠ°ΡΡΠΎΡΠ° ΠΎΡΠΈΠ±ΠΎΠΊ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΡΠ°Π΄ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠ°ΠΊΠ° ΠΏΡΠΎΡΡΠ°ΡΡ Π²ΡΡΠΎΠΊΠ°. Π’Π°ΠΊ, ΠΏΡΠΈ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π° Π² 30β50% ΡΠ»ΡΡΠ°Π΅Π² ΠΎΠΏΡΡ ΠΎΠ»ΠΈ ΡΠ’2 ΡΠ°ΡΡΠ΅Π½ΠΈΠ²Π°ΡΡΡΡ ΠΊΠ°ΠΊ ΡΠ’Π, Π° 10β15% Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΠΊΠ°ΡΠ΅Π³ΠΎΡΠΈΠ΅ΠΉ ΡΠ’Π ΠΈΠΌΠ΅ΡΡ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΡΡ ΡΡΠ°Π΄ΠΈΡ ΡΠ’4. Π‘ ΡΠ΅Π»ΡΡ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΡ ΡΠΎΡΠ½ΠΎΡΡΠΈ ΠΏΡΠ΅Π΄ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΡΡΠ°Π΄ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠ°ΠΊΠ° ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
- Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- ΠΡΠ΄Π΅ΡΠΆΠΊΠ°
- ΠΠΈΡΠ΅ΡΠ°ΡΡΡΠ°
- ΠΡΡΠ³ΠΈΠ΅ ΡΠ°Π±ΠΎΡΡ
- ΠΠΎΠΌΠΎΡΡ Π² Π½Π°ΠΏΠΈΡΠ°Π½ΠΈΠΈ
Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- ΠΠ»Π°Π²Π° 1. ΠΠ±Π·ΠΎΡ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- 1. 1. ΠΡΠΈΠ±ΠΊΠΈ ΡΡΠ°Π΄ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠ°ΠΊΠ° ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ
- 1. 2. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈ ΡΠ°ΠΊΡΠΎΡΡ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° ΠΏΡΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΠΎΠΌ ΡΠ°ΠΊΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ
- 1. 2. 1. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠ°Π΄ΠΈΠΊΠ°Π»ΡΠ½ΠΎΠΉ ΠΏΡΠΎΡΡΠ°ΡΡΠΊΡΠΎΠΌΠΈΠΈ ΠΏΡΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΠΎΠΌ ΡΠ°ΠΊΠ΅ ΠΏΡΠΎΡΡΠ°ΡΡ
- 1. 2. 2. Π€Π°ΠΊΡΠΎΡΡ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, ΠΏΠΎΠ΄Π²Π΅ΡΠ³Π½ΡΡΡΡ ΡΠ°Π΄ΠΈΠΊΠ°Π»ΡΠ½ΠΎΠΉ ΠΏΡΠΎΡΡΠ°ΡΡΠΊΡΠΎΠΌΠΈΠΈ
- 1. 2. 3. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ Π΄ΠΈΡΡΠ°Π½ΡΠΈΠΎΠ½Π½ΠΎΠΉ Π»ΡΡΠ΅Π²ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΏΡΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΠΎΠΌ ΡΠ°ΠΊΠ΅ ΠΏΡΠΎΡΡΠ°ΡΡ
- 1. 2. 4. Π€Π°ΠΊΡΠΎΡΡ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, ΠΏΠΎΠ΄Π²Π΅ΡΠ³Π½ΡΡΡΡ Π»ΡΡΠ΅Π²ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ
- 1. 2. 5. ΠΠ»ΠΈΡΠ½ΠΈΠ΅ ΠΌΠ΅ΡΠΎΠ΄Π° Π»Π΅ΡΠ΅Π½ΠΈΡ Π½Π° Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΡ Π±ΠΎΠ»ΡΠ½ΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ
- 2. 1. ΠΠ±ΡΠ°Ρ Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ° Π±ΠΎΠ»ΡΠ½ΡΡ
- 2. 2. ΠΠ΅ΡΠ΅Π½ΠΈΠ΅ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ 46 ΠΆΠ΅Π»Π΅Π·Ρ
- 2. 2. 1. Π₯ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Π±ΠΎΠ»ΡΠ½ΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ 46 ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ
- 2. 2. 2. ΠΠΈΡΡΠ°Π½ΡΠΈΠΎΠ½Π½Π°Ρ ΠΊΠΎΠ½ΡΠΎΡΠΌΠ½Π°Ρ Π»ΡΡΠ΅Π²Π°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ 50 Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ
- 2. 3. ΠΠ΅ΡΠΎΠ΄Ρ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΠ°Π±ΠΎΡΠΊΠΈ Π΄Π°Π½Π½ΡΡ
- 3. 1. ΠΡΠΈΠ±ΠΊΠΈ ΡΡΠ°Π΄ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΠ°ΠΊΠ° 53 ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ
- 3. 1. 1. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π°
- 3. 1. 2. ΠΡΠΈΠ±ΠΊΠΈ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΠ°ΠΊΠ° 56 ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ
- 3. 1. 2. 1. ΠΡΠΈΠ±ΠΊΠΈ Π² Π΄ΠΎΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΉ ΠΎΡΠ΅Π½ΠΊΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Ρ ΠΠ»ΠΈΡΠΎΠ½Π°
- 3. 1. 2. 2. ΠΡΠΈΠ±ΠΊΠΈ Π² ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΠΈ ΠΊΠ°ΡΠ΅Π³ΠΎΡΠΈΠΈ Π’
- 3. 1. 2. 3. ΠΡΠΈΠ±ΠΊΠΈ Π² ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΠΈ ΠΊΠ°ΡΠ΅Π³ΠΎΡΠΈΠΈ N
- 3. 2. 1. ΠΠ΅ΠΏΠΎΡΡΠ΅Π΄ΡΡΠ²Π΅Π½Π½ΡΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠ°Π΄ΠΈΠΊΠ°Π»ΡΠ½ΠΎΠΉ ΠΏΡΠΎΡΡΠ°ΡΡΠΊΡΠΎΠΌΠΈΠΈ Ρ 63 Π±ΠΎΠ»ΡΠ½ΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ
- 3. 2. 2. Π€ΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠ°Π΄ΠΈΠΊΠ°Π»ΡΠ½ΠΎΠΉ ΠΏΡΠΎΡΡΠ°ΡΡΠΊΡΠΎΠΌΠΈΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ 64 ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ
- 3. 2. 3. ΠΠ΅ΠΏΠΎΡΡΠ΅Π΄ΡΡΠ²Π΅Π½Π½ΡΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ Π΄ΠΈΡΡΠ°Π½ΡΠΈΠΎΠ½Π½ΠΎΠΉ ΠΊΠΎΠ½ΡΠΎΡΠΌΠ½ΠΎΠΉ Π»ΡΡΠ΅Π²ΠΎΠΉ 66 ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ
- 3. 2. 4. Π€ΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ Π΄ΠΈΡΡΠ°Π½ΡΠΈΠΎΠ½Π½ΠΎΠΉ ΠΊΠΎΠ½ΡΠΎΡΠΌΠ½ΠΎΠΉ Π»ΡΡΠ΅Π²ΠΎΠΉ 67 ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- ΠΠ°Π²ΡΠ΄ΠΎΠ² Π.Π., ΠΠΊΡΠ΅Π»Ρ Π. Π. Π‘ΡΠ°ΡΠΈΡΡΠΈΠΊΠ° Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ Π² Π ΠΎΡΡΠΈΠΈ ΠΈ ΡΡΡΠ°Π½Π°Ρ Π‘ΠΠ Π² 2006 Π³ΠΎΠ΄Ρ. -ΠΠΎΡΠΊΠ²Π° 2008. -ΡΡΡ. 50,61.
- Sobin LH and Wittekind Ch (eds). TNM Classification of Malignant Tumors. 6th edn. -Wiley-Liss:New York, 2002.
- Schroder FH. Management of locally advanced prostate cancer. Staging, natural history, and results of radical surgery.// -World J Urol. -2000 Jun- -18(3):-pp. 194−203.
- Martinez de la Riva SI, Lopez-Tomasety JB, Marrero Dominguez R, Santamaria Blanco P. Perineal radical prostatectomy as monotherapy: ten-year experience.// Arch Esp Urol. — 2004 May- -57(4) -pp. 397−411.
- Bhojani N. S. Ahyai, M. Graefen et al. Partin Tables cannot accurately predict the pathological stage at radical prostatectomy// J Urol. 2008- -1090.- v.l. -pp.l 10−114.
- Π.Π. Π‘ΡΠΊΠΎΠ½ΠΊΠΎ, Π. Π. Π ΠΎΠ»Π΅Π²ΠΈΡ, C.JI. ΠΠΎΠ»ΡΠΊΠΎΠ² ΠΈ Π΄Ρ. Π ΠΎΠ»Ρ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΠ°Π΄ΠΈΠΈ, ΡΡΠΎΠ²Π½Ρ ΠΠ‘Π ΠΈ ΡΡΠΌΠΌΡ ΠΠ»ΠΈΡΠΎΠ½Π° Π² ΡΠ»ΡΡΡΠ΅Π½ΠΈΠΈ Π΄ΠΎΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΡΠ°ΠΊΠ° ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. Π. ΠΠ½ΠΊΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡ. — № 2- 2007. — ΡΡΡ.5659.
- Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein Π, Walsh PC. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.// J Urol. — 1993 Jul. — 150(1).-pp. 110−4.
- Smith J A Jr, Scardino PT, Resnick MI et al. Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial. J Urol 1997. — 157. — pp. 902−906.
- Levitt JM, Slawin KM. Prostate-specific antigen and prostate-specific antigen derivatives as predictors of benign prostatic hyperplasia progression.// Curr Urol Rep. 2007 Jul — 8. — v.4. — pp. 269−274.
- Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.// Urology. 1999 Mar. — 53. — v. 3. — pp. 581−589.
- Amiel J, Chevallier D, Peyrottes A et al. Clinicopathologic and biological correlations (PSA-PAP) in pathology of the prostate. Apropos of 150 cases.// J Urol (Paris). 1990. — 96. — v.4. — pp. l99−201.
- Serkin Faye B. M.D., Douglas W. Soderdahl M.D., Jennifer Cullen Ph.D., Patient risk stratification using Gleason score concordance and upgrading among men with prostate biopsy Gleason score 6 or 7, Available online 30 December 2008.
- Muntener M., J. Epstein, D. Hernandez et al.: Prognostic Significance of Gleason Score Discrepancies between Needle Biopsy and Radical Prostatectomy, J. Eur. Urology. 2008. — v. 53. — Issue 4. — pp. 767−776.
- Steuber Π’., M. Graefen, A. Haese et al. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. J Urol. 2006. — v.175. — pp. 939−944.
- Koh H., M.W. Kattan, P.T. Scardino et al. A nomogram to predict seminal vesicle invasion by the extent and location of cancer in systematic biopsy results. J Urol. 2003. — v. 170 — pp. 1203−1208.
- Chun F. K.-H., Karakiewicz P.I., Briganti A. et al. Prostate Cancer Nomograms: An Update.//Eur Urol. 2006. — v. 50. — pp. 914−916.
- Partin AW, Kattan MW, Subong EN et al. Combination of prostate -specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997. -227.-v. 18.-pp. 1445−1451.
- Cagiannos I., P. Karakiewicz, J.A. Eastham et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol. 2003. — v. 170. — pp. 1798−1803.
- Briganti A., F.K. Chun, A. Salonia et al., Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy, Eur Urol. 2006. — v. 49. — pp. 1019−1027.
- Remzi. M, M. Waldert, B. Djavan- Preoperative nomograms and Artificial Network (ANNs) for Identification of Surgical Candidates. EAU update series.-2005.-v.3.-pp. 63−71.
- Young H.H. The early diagnosis and radical cure of carcinoma of the prostate: Being a study of 40 cases and presentation of a radical operation which was carried out in 4 cases. Bull Johns Hopkins Hosp. 1905. — v. 16. -pp. 315−321.
- ΠΠ°ΡΠ²Π΅Π΅Π² Π.Π., ΠΡΡ Π°ΡΠΊΠΈΠ½ Π. Π., ΠΠ°ΡΠ²Π΅Π΅Π² Π. Π. Π Π°ΠΊ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ.- ΠΠΎΡΠΊΠ²Π°.-1999. -ΡΡΡ.43−46.
- Heidenreich A, Varga Z, V. Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol. 2002. — v. 167(4). — pp. 1681−1686.
- Stone N. N, Stock RG, Unger P. Laparoscopic pelvic lymph node dissection for prostate cancer: comparison of the externed and modified techniques. J. Urol. 1997-Nov.-v. 158(5).-pp.1891−1894.
- Bader P, Burkhard FC, Markwalder R, Studer UE. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol. 2002- — v. l68(2) -pp.514−518.
- Guimaraes MS, Quintal MM, Meirelles LR et al. Gleason score as predictor of clinicopathologic findings and biochemical (PSA) progression following radical prostatectomy.// Int Braz J Urol. 2008. — Jan-Feb. — v.34(l). — pp. 23−9.
- Davidson PJ, van den Ouden D, Schroeder FH. Radical prostatectomy: prospective assessment of mortality and morbidity. Eur Urol. 1996. -v.29(2). — pp. 168−173.
- Hautmann RE, Sauter TW, Wenderoth UK. Radical retropubic prostatectomy: morbidity and urinary continence in 418 consecutive cases. Urology. 1994. — v.43(2 Suppl). — v.47−51.
- Murphy GP, Mettlin C, Menck H et al. National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer. J Urol. 1994. — v. 152(5 Pt 2). -pp. 1817−1819.
- Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol. 1982. — Sep. — v.128(3). — pp. 492−7.
- Aus G., C.C. Abbou, D. Pacik, H.-P. Schmid, et al. and the EAU Working Group on Oncological Urology. EAU Guidelines on Prostate Cancer.//Eur Urol.-2001.-v. 40.-pp. 97−101.
- Bianco F.J. Jr., P.T. Scardino and J.A. Eastham, Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function («trifecta»), Urology 66. 2005. — Suppl. 5. — pp. 83−94.
- Han M, Partin AW, Pound CR et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001.-v. 28(3).-pp.555−565.
- Catalona WJ, Smith DJ. 5-year tumour recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol. -1994. -v. 152. -pp. 1837−1842.
- Hull GW, Rabbani F, Abbas F. et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002. -v. 167. -pp.528−534.
- Trapasso JG, deKernion JB, Smith RB et al. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol. -1994. -v. 152. -pp.1821 -1825.
- Zincke H, Oesterling JE, Blute ML et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol. -1994. v. 152(5 Pt 2). -pp.1850−1857.
- Ward JF, Zincke H, Bergstralh EJ, et al. The impact of surgical approach (nerve bundle preservation versus wide local excixion) on surgical margins and biochemical recurrence following radical prostatectomy. J Urol. 2004. -v. 172.-pp. 1328−1332.
- Walsh, P.C., Schlegel, P.N.: Radical pelvic surgery with preservation of sexual function. Ann. Surg, and Transactions of the American Surgical Association.-1988.-v. 106.-pp. 145−154.
- Poore RE, McCullough DL, Jarow JP. Puboprostatic ligament sparing improves urinary continence after radical retropubic prostatectomy.// Urology. -1998. -Jan. -v. 51(1). -pp. 67−72.
- Deliveliotis C, Protogerou V, Alargof E et al. Radical prostatectomy: bladder neck preservation and puboprostatic ligament sparing—effects on continence and positive margins. Urology. -2002 Nov. -v. 5. -pp. 855−8.
- Cheng L, Darson MF, Bergstralh EJ, Slezak J, Myers RP, Bostwick DG. Correlation of margin status and extraprostatic extension with progression of prostate carcinoma.// Cancer. -1999. -v. 9. -pp.1775−1782.
- Graefen M., Uwe HG, Hans Heinzer et al., Inducation, technique and outcome of retropubic nerve-sparing radical prostatectomy, EAU Update Series. -2005. -pp. 77−85.
- Patel VR, Thaly R, Shah Π (2007) Robotic radical prostatectomy: outcomes of 500 cases. ΠJU Int. -1999. -pp. 109−111.
- Roehl Π. A., M. Han, CG. Ramos and WJ. Catalona, Cancer Progression and survival rates following anatomical radical Retropubic Prostatectomy in 3,478 Consecutive Patients: long-term results. J. Urol. -2004. -v. 172. 910 914.
- Salomon L, Anastasiadis AG, Johnson CW et al. Seminal vesicle involvement after radical prostatectomy: predicting risk factors for progression.// Urology. -2003 Aug. -v. 2. -pp.304−309.
- Boorjian SA, Thompson RH, Siddiqui S et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.// J Urol. -2007 Sep. -v. 178(3 Pt 1). -pp. 864−870.
- Pfitzenmaier Jesco, Sascha Pahernik, Tina Tremmel et al. Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression?// BJU International. —2008. —v. 102. Issue 10. — pp. 1413−1418.
- Maru N, Ohori M, Kattan MW, Scardino PT, Wheeler TM Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens.// Hum Pathol. -2001 Aug. v.8. -pp. 828−833.
- May Matthias, Kaufmann Olaf, Hammermann Franze et al. Prognostic impact of lymphovascular invasion in radical prostatectomy specimens.//BJU. 2006. — v. 99. -pp. 539−544.
- Moul JW, Merseburger AS, Srivastava S. Molecular markers in prostate cancer: the role in preoperative staging.//Clin Prostate Cancer. 2002 Jun. — v. 1 .—pp. 42−50.
- Soloway MS, Pareek K, Sharifi R, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol. -2002. -v.167. —pp. 112−116.
- Kattan M.W., J.A. Eastham, A.M. Stapleton et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer, J Natl Cancer Inst 90. 1998. -pp. 766−771.
- Kattan M.W., T.M. Wheeler, P.T. Scardino. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol.-1999.-pp. 1499−1507.
- Stephenson A.J., P.T. Scardino, J.A. Eastham et al., Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy, J Natl Cancer Inst 98. 2006. -pp. 715−717.
- Stephenson A.J., P.T. Scardino and J.A. Eastham et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy, J Clin Oncol 23. -2005. -pp. 7005−7012.
- Graefen M., P.I. Karakiewicz, I. Cagiannos et al. Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer, J Clin Oncol 20 -2002. -pp. 951−956.
- Bianco F.J. Jr., M.W. Kattan, P.T. Scardino et al. Radical prostatectomy nomograms in black American men: accuracy and applicability, J Urol 170 — 2003. -pp. 73−76.
- Shahrokh F. Shariat, Jochen Walz, Claus G. Roehrborn et al. External Validation of a Biomarker-Based Preoperative Nomogram Predicts Biochemical Recurrence After Radical Prostatectomy, J Clin Oncol. -2008. -v. 26 -No 9. -pp. 1526−1531.
- P.L. Ross, C. Gerigk and M. Gonen et al., Comparisons of nomograms and urologists' predictions in prostate cancer, Semin Urol Oncol 20 2002. -pp. 82−88.
- Dotan Z.A., F J. Bianco Jr., F. Rabbani et al., Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan inpatients with an increasing PSA after radical prostatectomy, J Clin Oncol 23. -2005.-pp. 1962−1968.
- Slovin S.F., A.S. Wilton, G. Heller, H.I. Scher. Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Clin Cancer Res 11. -2005. -pp. 8669−8673.
- McGowan DG. The value of extended field radiation therapy in carcinoma of the prostate. International journal of radiation oncology, biology, physics. -1981.-v. 7.-pp. 1333−1339.
- Bagshaw M.A. et al. Radiotherapy of prostatic carcinoma: long- or short-term efficacy. -Urology. 1985. -pp. 25, 17.
- Spaas PG, Bagshaw MA, Cox RS. The value of extended field irradiation in surgically staged carcinoma of the prostate. Int J Radiat Oncol Biol Phys. -1988.-v. 15.-pp. 133.
- Asbell SO, Krall JM, Pilepich MV et al. Elective irradiation in stage A2, Π carcinoma of the prostate: analysis of RTOG 77 06. Int J Radiation Oncology Biol Phys. -1988. -v.15(6). -pp. 1307−1316.
- Seaward S.A., Weinberg V., Levis P. et al. Improved freedom from PSA failure with whole pelvic irradiation for high risk prostate cancer.// Int.J.Radiat.Oncol.Biol.Phys. — 1998. — v. 42. -pp. 1055.
- Diaz A., Roach M., Marquez C. et al. Indications for and significance of seminal vesicles irradiation during 3D conformal radiotherapy for localized prostate cancer .//Int.J.Radiat.Oncol.Biol.Phys. 1994. — v. 40. — pp. 323.
- Katcher J., Kupelian P.A., Zippe C. et al. Indications for excluding the seminal vesicles when treating clinically localized prostatic adenocarcinomawith radiotherapy alone.// Int.J.Radiat.Oncol.Biol.Phys. 1997. — v. 37. -pp. 871.
- Hanks G.E., Martz K.L., Diamond J.J. The effectof dose on local control of prostate cancer.// Int.J.Radiat.Oncol.Biol.Phys. 1988. — v. 15. — pp. 1299.
- Pollack A., Zagars G.K. External-beam radiotherapy dose response of prostate cancer.// Int.J.Radiat.Oncol.Biol.Phys. 1997. — v. 39. — pp. 1011.
- Hancks G.E., Hanlon A.L., Schultheiss Π’.Π. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions.//Int.J.Radiat.Oncol.Biol.Phys. 1998. — v. 41. -pp. 501.
- Zelefsky M.J., Leibel S.A., Gaudin P.B. et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.// Int.J.Radiat.Oncol.Biol.Phys. 1998. — v. 41. — pp. 491.
- Soffen E.M., Hanks G.E., Hwang C.C. et al. Conformal static field therapy for low-volume low-grade prostate cancer with rigid immobilization.//Int.J.Radiat.Oncol.Biol.Phys. 1991. — v. 20. — pp. 141.
- Spaas P.G., Bagshaw M.A., Cox R.S. et al. The value of extended field irradiation in surgically staged carcinoma of the prostate.//Int.J.Radiat.Oncol.Biol.Phys. 1988. — v. 15 (Suppl. 1). — pp. 133.
- Pilepich M.V., Krall J.M., Sause W.T. et al. Correlation of radiotherapeutic parameters and treatment related morbidity in carcinoma of the prostate -analysis of RTOG study 75−06.//Int.J.Radiat.Oncol.Biol.Phys. 1987. — v. 13.-pp.351.
- Pilepich M.V., Krall J.M., Sause W.T. et al. Correlation of radiotherapeutic parameters and treatment related morbidity in carcinoma of the prostate — analysis of RTOG study 75−06.//Int.J.Radiat.Oncol.Biol.Phys. 1987. — v. 13.-pp.351.
- Soffen E.M., Hanks G.E., Hwang C.C. et al. Conformal static field therapy for low-volume low-grade prostate cancer with rigid immobilization.^.J.RadiatOncol.Biol.Phys. 1991. — v. 20. — pp. 141.
- Zelefsky M.J., Leibel S.A., Kutcher G.J. et al. Three-dimensional conformal radiotherapy and dose escalation: where do we stand?//Semin.Radiat.Oncol.- 1998.-v. 8.-pp. 107.
- Jeldres Claudio, Nazareno Suardi, Paul Perrotte et al. Survival after radical prostatectomy and radiotherapy for prostate cancer: a population-based study.// Can Urol Assoc J. -2009. -v. 3(1). -pp. 13−21.
- Zagards G.K. Prostate-specific antigen as an outcome variable for Tland T2 prostate cancer treated by radiation therapy.//J.Urol. 1994. — v. 152.-pp. 1786.
- Zietman A.L., Coen J.J., Shipley W.U. et al. Radical radiation therapy in the management of prostatic adenocarcinoma: the ibitial prostatic specific antigen value as a predictor of treatment outcome.//J.Urol. — 1994. — v. 151.- pp. 640.
- Shellhammer P.F., El-Mahdi A.M., Wright G.L. et al. Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of the prostate.//Urol. 1993. — v. 42. — pp. 13.
- American Society For Therapeutic Radiology and Oncology Consensus panel. Consensus statement: guidelines for PSA following radiation therapy.//Int.J.Radiat.Oncol.Biol.Phys. 1997. — v. 37. — pp. 1035.
- Hanks G.E., Krall G.M., Hanlon A.L. et al. Patterns of care and RTOG studies on the prostate cancer: long term survival, hazard rateobservation, and possibilities of cure.//Int J.Radiat.Oncol.Biol.Phys. 1993. -v. 28.-pp. 39.
- Shipley W.U., Prout G.M., Coashman P.L. et al. Radiation therapy for localized prostate carcinoma: experience at the Massachusetts General Hospital (1973−1981).//Natl.Cancer Inst.Monogr. 1988. — v. 7. — pp. 67.
- Zagards G.K. Prostate-specific antigen as an outcome variable for Tland T2 prostate cancer treated by radiation therapy.//J.Urol. 1994. — v. 152.-pp. 1786.
- Zagars G.K., Serum PSA as a tumor marker for patients undergoing definitive radiation therapy.//Urol.Clin.North Amer. 1993. — v. 20. — pp. 737.
- Pisansky T.M., Cha S.S., Earle J.D. et al. Prostate-specific antigen as a pre-therapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer.//J.Clin.Oncol. 1993. — v. 11. — pp. 2158.
- Kuban D.A., El-Mahdi A.M., Schellhammer P.F. Prostatic specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer.//Int.J.Radiat.Oncol.Biol.Phys.- 1995.-v. 32.-pp. 307−316.
- Fukunaga-Johnson N., Sandler H.M., McLaughlin P.W. et al. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer./ZInt.J.Radiat.Oncol.Biol.Phys. 1997. — v. 38. — pp. 311.
- Kuban D.A., El-Mahdi A.M., Schellhammer P.F. Prostatic specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer.//Int J.Radiat.Oncol.Biol.Phys.- 1995. v. 32. — pp. 307−316.
- Lee W.R. Hanks G.E., Schultheiss Π’.Π. et al. Localized prostate cancer treated by external beam radiotherapy alone: serum prostatic-specific antigen-driven outcome analysis.//J.Clin.Oncol. 1995. — v. 15. — pp. 464.
- D’Amico AV, Schultz D, Loffredo M, et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA. 2000. -v. 284. -pp.1280−1283.
- See WA et al. The bicalutamide Early Prostate Cancer Program. Demography. Urol. Oncol. -2001. -v.6. -pp. 43−47.
- Kattan MW, Potters L, Blasko JC, et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology. -2001. -v. 58. -pp. 393−399.
- Kattan M.W., M.J. Zelefsky, P.A. Kupelian et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer, J Clin Oncol 18. -2000. -pp. 3352−3359.
- Kattan M.W., M.J. Zelefsky, P.A. Kupelian et al. Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer, J Clin Oncol 21.-2003.-pp. 4568−4571.
- Stein A., DeKernion J.B., Smith R.B. et al. Prostatic-specific antigen levels after radical prostatectomy in patients with organ-confined and locally extensive prostate cancer.//J.Urol. 1992. — v. 147. — pp. 942.
- Albertsen PC, Hanley JA, Penson DF, Barrows G, Fine J. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort.// J Urol. -2007 Mar. -v. 177(3). pp. 932−936.
- Talcott J.A., Rieker P., Clark J.A. et al. Patient-reported symptoms after primary therapy for early prostate cancer: results of the prospective cohort study.//J.Clin.Oncol. 1997. — v. 16. — pp. 175.
- Walsh P.C. Radical retropubic prostatectomy with reduced morbidity: an anatomical approach.//Natl.Cancer Inst.Monogr. 1988. — v. 7. — pp. 133.
- Herr H.W. Quality of life in incontinent men after radical prostatectomy.//J.Urol. 1994. — v. 151. — pp. 652.
- Kirby R. Management of clinically localized prostate cancer by radical prostatectomy followed by watchful waiting.//Nat Clin Pract Urol. -2005. v. 2(6). — pp. 298−303.
- Eastham JA, Kattan MW, Riedel E, Begg CB, Wheeler TM, Gerigk C, et al. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol. —2003,-v. 170. -p.2292.
- Koch M., J. Smith, Jr. Blood Loss During Radical Retropubic Prostatectomy: Is Preoperative Autologous Blood Donation Indicated? The Journal of Urology. -2008. -v. 156. -pp. 1077−1080.
- Rainwater LM, Segura JW. Technical consideration in radical retropubic prostatectomy: blood loss after ligation of dorsal venous complex.// J Urol. -1990 Jun. -v. 143(6). -pp.1163−1165.
- Lepor H., Nieder A.M., Ferrandino M.N. Intraoperative and postoperative complications of radical retropubic prostatectomy in a consecutive series of 1,000 cases.//J Urol. 2001. — v. 166(5). — pp. 172 933.
- Heinzer H., Hammerer P., Graefen M. et al. Thromboembolic complication rate after radical retropubic prostatectomy. Impact of routine ultrasonography for the detection of pelvic lymphoceles and hematomas.//Eur Urol. 1998. — v. 33(1). — pp. 86−90.
- Pepper R.J., Pati J., Kaisary A.V. The incidence and treatment of lymphoceles after radical retropubic prostatectomy.//BJU Int. 2005. — v. 95(6). -pp. 772−775.
- Solberg A., Angelsen A., Bergan U. et al. Frequency of lymphoceles after open and laparoscopic pelvic lymph node dissection in patients with prostate cancer.//Scand J Urol Nephrol. 2003. — v. 37(3). — pp. 218−21.
- Wagner A.A., Link R.E., Trock B.J. et al. Comparison of open and laparoscopic radical prostatectomy outcomes from a surgeon’s early experience./AJrology. — 2007. v. 70(4). — pp. 667−71.
- Kundu S.D., Roehl K.A., Eggener S.E. et al. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies.//J. Urol. 2004. — v. 172(6). — pp. 2227−31.
- Critz F.A., Levinson A.K., Griffin V.D. The PSA Nadir Goal for Radiotherapy of Prostate Cancer is 0.2 NG/ML.//J Urol. -1998. -v. 159. -p. 218.
- Alcantara Pino, MD, Alexandra Hanlon, PhD, Mark K. Buyyounouski, MD. Prostate-Specific Antigen Nadir Within 12 Months of Prostate Cancer Radiotherapy Predicts Metastasis and Death.//Cancer -2007. -v.109 (1). -pp. 41−47.